+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors



Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors



Clinical Advances in Hematology and Oncology 1(1): 41-48



Angiogenesis is an important natural process occurring in the body, both in health and in infirmity, that is controlled by angiogenesis-stimulating growth factors and angiogenesis inhibitors. Uncontrolled angiogenesis in a tumor can result in both tumor growth and metastasis. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are major players in many human malignancies and contribute directly to disease outcome. There is compelling evidence indicating that the beneficial effects of VEGF and VEGFR can be targeted as antiangiogenic therapy. Many of the agents have shown promising results in cell culture preclinical and animal models. Some of these agents have been tested in clinical trials as well. This review discusses the clinical significance of VEGF/VEGFR in human cancer, summarizes the more recent progress in the field, and further emphasizes the current development of agents that block VEGFR/VEGFR as angiogenesis inhibitors and the therapeutic significance of these agents in clinical trials.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048274730

Download citation: RISBibTeXText

PMID: 16227959


Related references

Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. Expert Opinion on Investigational Drugs 11(10): 1447-1465, 2002

Rational Design of Antiangiogenic Helical Oligopeptides Targeting the Vascular Endothelial Growth Factor Receptors. Frontiers in Chemistry 7: 170, 2019

Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies. Current Cancer Drug Targets 5(4): 229-248, 2005

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets 5(4): 229-248, 2005

Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Research 59(21): 5412-5416, 1999

Vascular Endothelial Growth Factor (VEGF), VEGF Receptors and Their Inhibitors for Antiangiogenic Tumor Therapy. Biological & Pharmaceutical Bulletin 34(12): 1785-1788, 2011

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biological and Pharmaceutical Bulletin 34(12): 1785-1788, 2011

Vascular endothelial growth factor as a target for antiangiogenic therapy. Journal of Clinical Oncology 18(21 Suppl): 45s-46s, 2000

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Molecular Cancer Therapeutics 5(12): 3105-3112, 2006

Double-antiangiogenic protein DAAP targeting vascular endothelial growth factor A and angiopoietins attenuates collagen-induced arthritis. Arthritis Research & Therapy 15(4): R85-R85, 2015

Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation 130(13): 1072-1080, 2014

Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy. Advances in Oto-Rhino-Laryngology 62: 103-120, 2005

Antiangiogenic therapy of tumors using a vascular endothelial growth factor Diphtheria toxin conjugate. European Journal of Clinical Investigation 28(Suppl. 1): A42, 1998

Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Experimental Biology and Medicine 235(1): 3-9, 2010

Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proceedings of the National Academy of Sciences of the United States of America 92(14): 6374-6378, 1995